UBS downgrades CureVac (CVAC) to a Hold
UBS analyst Eliana Merle downgraded CureVac (CVAC – Research Report) to a Hold today and set a price target of $5.50. The company’s shares closed yesterday at $5.44.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Merle covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Ascendis Pharma, and BioNTech SE. According to TipRanks, Merle has an average return of -5.4% and a 38.24% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for CureVac with a $6.33 average price target, which is a 16.36% upside from current levels. In a report released on June 13, Jefferies also downgraded the stock to a Hold with a $5.00 price target.
The company has a one-year high of $5.72 and a one-year low of $2.37. Currently, CureVac has an average volume of 1.18M.
Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CVAC in relation to earlier this year.
Read More on CVAC:
